| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $56.9M+30.5% | $43.6M+17.5% | $37.1M+28.9% | $28.8M+180.1% | $10.3M-94.7% | $192.2M+51.3% | $127.1M+66.0% | $76.6M+58.4% | $48.3M |
| Research and development | $71.4M-1.5% | $72.5M-12.0% | $82.4M-8.8% | $90.4M+18.1% | $76.5M+56.4% | $48.9M+59.4% | $30.7M+111.6% | $14.5M+17.2% | $12.4M |
| Sales and marketing | $102.6M+25.2% | $82.0M-2.5% | $84.1M-12.5% | $96.0M+24.3% | $77.2M+43.4% | $53.9M+38.5% | $38.9M+79.5% | $21.7M+69.2% | $12.8M |
| General and administrative | $107.6M-14.0% | $125.1M+5.3% | $118.8M+18.4% | $100.4M+33.9% | $75.0M+53.6% | $48.8M+33.6% | $36.5M+59.0% | $23.0M+14.3% | $20.1M |
| Litigation settlement expense | $5.7M+105.9% | -$96.3M-200.0% | $96.3M | — | — | — | — | — | — |
| Total operating expenses | $410.6M+40.1% | $293.0M-39.4% | $483.7M+21.2% | $399.0M+22.4% | $326.1M+51.9% | $214.7M+41.6% | $151.6M+64.5% | $92.1M+95.0% | $47.2M |
| (Loss) income from operations | -$30.8M-175.5% | $40.8M+120.0% | -$203.4M-163.3% | -$77.2M-159.8% | -$29.7M-32.0% | -$22.5M+8.2% | -$24.5M-57.5% | -$15.6M+23.2% | -$20.3M |
| Interest income, net | $9.2M-22.0% | $11.8M-0.9% | $11.9M+215.4% | $3.8M+2251.3% | $160K-41.0% | $271K-72.5% | $985K+126.6% | -$3.7M+36.9% | -$5.9M |
| Other income, net | $524K+59.3% | $329K-75.7% | $1.4M+147.1% | -$2.9M-9.3% | -$2.6M-224.0% | -$811K-12.8% | -$719K-303.9% | -$178K+82.7% | -$1.0M |
| Total other income | $9.7M-19.8% | $12.1M-8.5% | $13.2M+1226.0% | $997K+142.2% | -$2.4M-185.0% | $2.8M+374.9% | $585K+101.8% | -$32.6M+11.7% | -$37.0M |
| (Loss) income before income taxes | -$21.1M-139.9% | $52.9M+127.8% | -$190.1M-149.4% | -$76.2M-137.6% | -$32.1M-62.5% | -$19.8M+17.5% | -$23.9M+50.3% | -$48.2M+15.8% | -$57.3M |
| Income tax expense | -$271K+12.6% | -$310K-119.9% | -$141K+62.8% | -$379K-126.6% | $1.4M+37.6% | $1.0M-47.7% | $2.0M+38.0% | $1.4M-16.1% | $1.7M |
| Net (loss) income | -$21.4M-140.6% | $52.5M+127.6% | -$190.3M-148.4% | -$76.6M-149.9% | -$30.7M-63.8% | -$18.7M | — | -$46.8M+15.7% | -$55.5M |
| Basic (in dollars per share) | -$400.00-140.0% | $1000.00+128.2% | -$3540.00-145.8% | -$1440.00-144.1% | -$590.00-47.5% | -$400.00+23.1% | -$520.00+60.3% | -$1310.00-54942.0% | -$2.38 |
| Diluted (in dollars per share) | -$400.00-143.0% | $930.00+126.3% | -$3540.00-145.8% | -$1440.00-144.1% | -$590.00-47.5% | -$400.00+23.1% | -$520.00+60.3% | -$1310.00-54942.0% | -$2.38 |
| Basic (in shares) | 53.29B+1.0% | 52.77B-1.8% | 53.76B+0.8% | 53.32B+2.1% | 52.24B+12.4% | 46.48B+10.3% | 42.15B+18.3% | 35.64B+152643.8% | 23.3M |
| Diluted (in shares) | 53.29B-5.9% | 56.62B+5.3% | 53.76B+0.8% | 53.32B+2.1% | 52.24B+12.4% | 46.48B+10.3% | 42.15B+18.3% | 35.64B+152643.8% | 23.3M |
| Testing services revenue | |||||||||
| Cost of testing services, product, patient and digital solutions | $38.2M+24.8% | $30.6M+17.9% | $26.0M+16.6% | $22.3M+209.2% | $7.2M+35.0% | $5.3M-82.0% | $29.6M+38.1% | $21.5M | — |
| Product revenue | |||||||||
| Patient and digital solutions revenue | |||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.